Antituberculosis activity of clarithromycin

J. Luna-Herrera, V. M. Reddy, D. Daneluzzi, P. R.J. Gangadharam

Research output: Contribution to journalArticlepeer-review

52 Scopus citations

Abstract

Antituberculosis activity of clarithromycin (CLA), a macrolide antibiotic, was investigated in vitro, in macrophages, and in C57BL/6 mice. CLA showed high in vitro MICs (4 to > 16 μg/ml) for several strains of Mycobacterium tuberculosis and caused slight enhancement of activity of rifampin (RIF) against H37Rv but failed to increase the activity of either RIF or isoniazid (INH) against other strains. However, inside J774A.1 macrophages, CLA showed high activity and was synergistic with RIF against some strains of tubercle bacilli susceptible or resistant to INH and RIF. In the in vivo studies with a drug-susceptible strain (H37Rv), CLA protected mice from mortality due to tuberculosis for up to 8 weeks of observation. The CFU data for lungs and spleens revealed that the antituberculosis activity of CLA is inferior to those of INH and streptomycin. However, the activity of CLA when used alone or in combination was comparable to that of thiacetazone, indicating its potential usefulness as a secondary drug for the treatment of tuberculosis.

Original languageEnglish
Pages (from-to)2692-2695
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Volume39
Issue number12
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

Dive into the research topics of 'Antituberculosis activity of clarithromycin'. Together they form a unique fingerprint.

Cite this